On May 13, 2025, iTeos Therapeutics, Inc. announced that its subsidiary, iTeos Belgium S.A., will terminate its Collaboration and License Agreement with GlaxoSmithKline for the development of belrestotug, effective six months from the notice date. This decision follows topline interim results from a related study, signaling a significant shift in their collaboration.